Overview

A Study of YM178 in Subjects With Symptoms of Overactive Bladder

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This study is to assess the efficacy and safety of YM178 in patients with symptoms of overactive bladder.
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Mirabegron
Tolterodine Tartrate